AdvisorShares Investments’s Psyence Biomedical PBM Stock Holding History

AdvisorShares Investments’s Portfolio PBM Stock Details PBM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-860	Closed	-$17.2K	–	362
2025 Q3	$17.2K	Buy	860 +148	+21%	+$4.07K	﹤0.01%	287
2025 Q2	$23.7K	Hold	712	–	–	﹤0.01%	287
2025 Q1	$21K	Buy	712 +172	+32%	+$10.9K	﹤0.01%	266
2024 Q4	$56.8K	Buy	540 +210	+64%	+$50K	0.01%	252
2024 Q3	$123K	Buy	330 +206	+166%	+$279K	0.02%	247
2024 Q2	$148K	Buy	124 +51	+70%	+$153K	0.03%	237
2024 Q1	$309K	Buy	+73	New	+$305K	0.05%	211

Other funds holding PBM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SFFS

Stonehage Fleming Financial Services St. Helier, Jersey $2.75B AUM 13.81% 1-Year Est. Return

AdvisorShares Investments's PBM Position: Q4 2025 in Review

AdvisorShares Investments sold out of Psyence Biomedical (PBM) in Q4 2025, closing a stake of 860 shares — an estimated $17.2K sold.

AdvisorShares Investments first reported a position in PBM in Q1 2024 and held it in 7 quarters. The position peaked at $309K in Q1 2024. 5 funds tracked by Wall St. Rank hold PBM as of Q4 2025.

AdvisorShares Investments reported no remaining Psyence Biomedical position as of Q4 2025 after selling out during the quarter.
AdvisorShares Investments sold 860 Psyence Biomedical shares in Q4 2025, an estimated $17.2K.
AdvisorShares Investments first reported a position in Psyence Biomedical in Q1 2024 and held it in 7 quarters.
AdvisorShares Investments's Psyence Biomedical position peaked at $309K in Q1 2024.
5 funds tracked by Wall St. Rank held Psyence Biomedical as of Q4 2025.

Based on AdvisorShares Investments's 13F filing for Q4 2025, filed 10 Feb 2026.